Astex Pharmaceuticals Inc (ASTX)

Astex Pharmaceuticals, Inc. discovers and develops small-molecule therapeutics with a focus on oncology and hematology. It provides Pyramid, a fragment-based drug discovery platform. The company offers Dacogen (decitabine) for injection for the treatment of patients with myelodysplastic syndrome (MDS). Its products include SGI-110, a small molecule DNA-hypomethyating agent that treats MDS, acute myeloid leukemia, platinum resistant ovarian cancer, and hepatocellular carcinoma; and AT13387, a small molecule inhibitor for Hsp90, which studies patients with refractory gastrointestinal stromal tumors, castration resistant prostate cancer, and non-small cell lung cancer. Its products also comprise AT7519, a small molecule targeted inhibitor of several cyclin-dependent kinases, which combines bortezomib in patients with multiple myeloma; AT9283, a small molecule inhibitor of kinases that studies chemotherapy refractory multiple myeloma patient population and pediatric leukemia; and Amuvatinib, a multi-targeted tyrosine kinase inhibitor that studies cancer treatment. In addition, it, together with its partners, develops LEE011, a selective inhibitor of CDK4 and CDK6 in Phase I and Phase I/II clinical trials; JNJ42756493 FGFr inhibitor that is in Phase I clinical trial for cancer treatment; AZD3293, a Phase I clinical trial product for treating Alzheimer’s disease; and AT13148—ACG Kinase Inhibitor that is in Phase I clinical trial. Astex Pharmaceuticals, Inc. was formerly known as SuperGen Inc. and changed its name to Astex Pharmaceuticals, Inc. in September 2011. The company was founded in 1991 and is based in Pleasanton, California with an additional office in Cambridge, United Kingdom. Astex Pharmaceuticals, Inc. operates as a subsidiary of Otsuka America, Inc.